Darmiyan

Darmiyan offers AI-driven brain imaging tools intended to detect neurodegenerative disease at early stages, with a focus on Alzheimer's and brain health screening. They position their technology as non-invasive, accurate, and integrated for use by clinicians, researchers, and pharma partners.

Darmiyan specializes in brain imaging software that analyzes MRI scans at the cellular level to quantify changes in brain tissue architecture. Their BrainSee software utilizes neuroscience-powered AI to grade the intercellular space within brain images, enabling a suite of brain tests and diagnostic tools that are non-invasive and designed for integration into clinical workflows. The company highlights FDA-related milestones and a mission to provide early detection and monitoring of interventions, with a target of enabling a range of tests starting with an Alzheimer’s test.

Who it’s for: Healthcare providers (clinicians and imaging centers), pharmaceutical companies, and research institutions focused on brain health and neurodegenerative diseases.

Funding/Investor activity mentioned (e.g., round led by Eisai), FDA/Breakthrough designation news, media coverage and CEO awards indicate traction and maturation.